Based on the clinical features of our patients, this study provides significant evidence that the downregulation of HOXB1 is associated with worse survival and that the level of HOXB1 expression is an independent predictor of prognosis in glioma patients. This evidence concerns the gene HOXB1 and central nervous system cancer.